Abstract: Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro. In particular, the disclosure relates to variants of olivetolic acid cyclase.

Abstract: The present disclosure relates to variants of SARS-CoV-2 nucleocapsid protein, spike protein, and spike protein receptor binding domain (RBD), as well as nucleic acids encoding such variants and methods of use thereof. Such variants are useful in diagnostic test kits and vaccines for SARS-CoV-2.

Abstract: Aspects of the disclosure relate to biosynthesis of histidine in host cells. For example, host cells may comprise: a promoter; a ribosome binding site (RBS); and a nucleic acid comprising: hisG; hisD; hisC hisB; hisH; hisA; hisF; and/or hisI. Host cells may further comprise a nucleic acid encoding a ribose phosphate pyrophosphokinase (RPPK), optionally comprising one or more amino acid substitutions relative to the sequence of wildtype E. coli RPPK. Host cells of the disclosure may comprise a nucleic acid encoding a 5,10-methylene-tetrahydrofolate dehydrogenase/5,10-methylene-tetrahydrofolate cyclohydrolase (MTHFDC) enzyme. Further aspects of the disclosure relate to production of purine pathway metabolites and/or plasmid DNA in host cells.

Abstract: Described in this disclosure are rare earth element (REE)-binding proteins (e.g., lanthanide-binding proteins), host cells expressing the REE-binding proteins, and methods of recovering REEs.

Abstract: Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro.

Abstract: Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro.

Abstract: Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro.

Abstract: Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro.